

## DATA SHEET – CEF-Peptide-Pool<sup>+</sup>

---

Catalog No.:	PA-CEF-002
Product:	CEF – Peptide – Pool <sup>+</sup>
Formulation:	Lyophilized
Description:	This pool contains 32 HLA class I-restricted T-cell epitopes from human Cytomegalovirus, Epstein-Barr virus and Influenza virus. The CEF-Pool stimulates the release of IFN-gamma from CD8 <sup>+</sup> T-cells in individuals with certain highly frequent HLA types (HLA: A1, A2, A3, A11, A24, A68, B7, B8, B27, B35, B44). The CEF Peptide Pool ist useful as a peptide-specific positive control in ELISPOT, CTL and Intracellular Cytokine Assays using human PBMC.
Short-time Storage:	+4 °C
Long-time Storage:	-20 °C
Recommended test concentration:	For Elispot we recommend the following usage: 2µg of each peptide/ml with a final volume of 100µl/well (0.2µg of each peptide/well). For other T cellular assays (e.g. cytokine flow cytometry) the optimum conditions should be tested by the customer.
Dissolving:	Add 1ml of cell culture medium (e.g. RPMI 1640) per vial. Dissolve the peptide pool by vortexing three times for 1 minute (stock solution).
Working solution:	Dilute the stock solution (20µg of each Peptide/ml) 1:5 with cell culture medium to a concentration of 4µg of each peptide/ml.
Aliquotation:	Freeze 50µl Aliquots (-20 °C). One 50µl aliquot is sufficient to analyze 1 ELISPOT sample.
Containing Peptides:	VSDGGPNLY (Influenza A, HLA-A1), CTELKLSDY (Influenza A, HLA-A1), GILGFVFTL (Influenza A, HLA-A2), FMYSDFHFI (Influenza A, HLA-A2), CLGGLLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2), KTGGPYKR (Influenza A, HLA-A68), RVLSFIKGTK (Influenza A, HLA-A3), ILRGSVAHK (Influenza A, HLA-A3), RVRAYTYSK (EBV, HLA-A3), RLRAEAQVK (EBV, HLA-A3), SIIPSGPLK (Influenza A, HLA-A3/A11/A6), AVFDRKSDAK (EBV, HLA-A11), IVTDFSVIK (EBV, HLA-A11), ATIGTAMYK (EBV, HLA-A11), DYC NVLNKEF (EBV, HLA-A24), LPFDKTTVM (Influenza A, HLA-B7), RPPIFIRRL (EBV, HLA-B7), ELRSRYWAI (Influenza A, HLA-B8), RAKFKQLL (EBV, HLA-B8), FLRGRAYGL (EBV, HLA-B8), OAKWRLQTL (EBV, HLA-B8), SDEEEAIVAYTL (HCMV, HLA-B18), SRYWAIRTR (Influenza A, HLA-B27), ASCMGLIY (Influenza A, HLA-B27), RRIYDLIEL (EBV, HLA-B27), YPLHEQHGM (EBV, HLA-B35), IPSINVHHY (HCMV, HLA-B35), EENLLDFVRF (EBV, HLA-B44), EFFWDANDIY (HCMV, HLA-B44), TPRVTGGGAM (HCMV, HLA-B7).

- References:
- (1) Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. *J Immunol Methods* 260:157-172, 2002.
  - (2) NIH AIDS Research & Reference Reagent Program  
[www.aidsreagent.org/UploadDocs/9808\\_001.pdf](http://www.aidsreagent.org/UploadDocs/9808_001.pdf)

Attention: **For research use only, not for diagnostic use! Not for use in humans.**